after the adoption of the PLFSS, Sébastien Lecornu ensures that the federal government is now “mobilizing” for the vote on the state funds | EUROtoday

The skilled group of French biotechs, France Biotech, referred to as on Tuesday parliamentarians to withdraw an modification adopted by the Senate aimed toward suspending public assist in 2026, as a part of the finance invoice.

“A brutal call into question of public support would permanently weaken this ecosystem already subject to strong financial constraints”alerts France Biotech in a press launch, calling on parliamentarians “not to validate this amendment” to the state funds, tabled by Senator Jean-François Husson (Les Républicains, LR) who proposes to droop in 2026 the allocation of any new assist from the France 2030 plan.

“The 2025 financial year has once again demonstrated the government’s difficulty in managing aid from the France 2030 plan in a reliable and transparent manner, despite the crisis situation affecting the public accounts”underlines this modification.

France Biotech asks “the withdrawal of this amendment or, at a minimum, the explicit exclusion of SMEs from its scope, in order to preserve the sustainability of health innovation and national health sovereignty”.

The affiliation recollects that “the projects supported in this framework are part of long cycles of research, development and industrialization”. So, “any sudden interruption weakens projects already underway, sometimes at critical stages of their development”she warns.

The suspension of France 2030 assist would, based on her, “a significant impact” on their monetary well being already “particularly tense”marked by difficulties to find funds.

At first studying, deputies rejected the draft state funds for 2026, whereas senators adopted it on Monday in a revised model. Seven deputies and 7 senators should now meet on Friday in a joint committee (CMP) to attempt to discover an settlement.